Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Wednesday 30 January, 2019

Evgen Pharma PLC

Grant of Options

RNS Number : 5963O
Evgen Pharma PLC
30 January 2019
 

For immediate release                                                                                                                 30 January 2019

 

 

 

 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 28 January 2019, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 826,743 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

PDMR

Position

Options granted

Dr Stephen Franklin

Chief Executive Officer

471,061      

 

Richard Moulson

Chief Financial Officer

155,682

 

Sally Ross

Clinical Development Officer

200,000

 

The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 28 January 2018.

These nil cost options are subject to the rules of the LTIP. The options will vest on the third anniversary of grant subject to a minimum absolute total shareholder return (TSR) from the grant date to the vesting date of 10%, at which 25% of the awards will vest, and then on a straight line basis to a 20% TSR at which 100% of the awards will vest. Re-testing of this performance condition after the vesting date is not permitted.

 

Enquiries:

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

 

c/o +44 (0) 20 7466 5000

finnCap

Geoff Nash, Teddy Whiley (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

www.finncap.com

 

 +44 (0) 20 7220 0500

WG Partners LLP

Nigel Barnes, Claes Spång

 

+44 (0) 20 3705 9330

Buchanan

Mark Court, Sophie Wills, Tilly Abraham

[email protected]

 

 +44 (0) 20 7466 5000

 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Steve Franklin

2

Reason for the notification

a)

Position/status

Chief Executive

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

471,061

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

28 January 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

155,682

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

28 January 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Sally Ross

2

Reason for the notification

a)

Position/status

Clinical Development Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

  200,000

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

28 January 2019

g)

Place of the transaction

London Stock Exchange, AIM

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHSDLFWSFUSEEF

a d v e r t i s e m e n t